跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE
Approved
STANDARD
REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE
Bristol-Myers Squibb Pharma Eeig
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Aug 17, 2020
Approval ID
c87b7d21e287476a
Company
Bristol-Myers Squibb Pharma Eeig
Type
Standard
Approval Details
Approval Id
c87b7d21e287476a
Drug Cima Aemps Name
REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE
Register Number
1201452001
Holder Company Name
Bristol-Myers Squibb Pharma Eeig
Marketing Company Name
Bristol Myers Squibb S.A.
Holder Company Detail Path
/organization/bristol-myers-squibb-pharma-eeig
Authorization Date
2020-08-17
Dosage Form
POLVO PARA SOLUCIÓN INYECTABLE
Dose
25 mg
Route Of Administration
VÍA SUBCUTÁNEA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Bristol-Myers Squibb Pharma Eeig
Company Detail Path
/organization/bristol-myers-squibb-pharma-eeig
Company Information
Pharmaceutical Company Name
Bristol-Myers Squibb Pharma EEIG
Country Name
Ireland
Active Ingredients
LUSPATERCEPT
25 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Aug 17, 2020
Approval ID
c87b7d21e287476a
Type
Standard
Back to CIMA-AEMPS Approvals
